DoximityDOCS
DOCS
About: Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
Employees: 827
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
239% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 33
41% more repeat investments, than reductions
Existing positions increased: 152 | Existing positions reduced: 108
24% more capital invested
Capital invested by funds: $4.98B [Q3] → $6.17B (+$1.19B) [Q4]
20% more call options, than puts
Call options by funds: $125M | Put options by funds: $104M
19% more funds holding
Funds holding: 348 [Q3] → 415 (+67) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]
1.09% less ownership
Funds ownership: 91.27% [Q3] → 90.18% (-1.09%) [Q4]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$55
24%
downside
Avg. target
$70
3%
downside
High target
$90
24%
upside
10 analyst ratings
4 positive
40%
6 neutral
60%
0 negative
0%
Mizuho Steven Valiquette 40% 1-year accuracy 2 / 5 met price target | 10%downside $65 | Neutral Maintained | 10 Feb 2025 |
Goldman Sachs David Roman 50% 1-year accuracy 7 / 14 met price target | 11%upside $80 | Neutral Maintained | 10 Feb 2025 |
Leerink Partners Michael Cherny 67% 1-year accuracy 26 / 39 met price target | 24%upside $90 | Outperform Upgraded | 7 Feb 2025 |
Canaccord Genuity Richard Close 61% 1-year accuracy 17 / 28 met price target | 2%downside $71 | Hold Maintained | 7 Feb 2025 |
Raymond James Brian Peterson 48% 1-year accuracy 12 / 25 met price target | 15%upside $83 | Outperform Reiterated | 7 Feb 2025 |
Financial journalist opinion
Based on 19 articles about DOCS published over the past 30 days
Neutral
Business Wire
22 hours ago
DOXIMITY INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties – DOCS
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Doximity, Inc. (“Doximity”) (NYSE: DOCS) breached their fiduciary duties to Doximity and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members of Doximity's board of directors or senior management failed to manage Doximity in an acceptable manner, in breach of their fiduciary dut.
Positive
Seeking Alpha
1 week ago
Doximity: Rating Downgrade As Near-Term Upside Is Priced In
I downgraded Doximity from buy to hold due to expected growth slowdown and current high valuation at 40.5x forward EBITDA. DOCS reported strong Q3 performance with $168.6 million revenue, 25% y/y growth, and 93.3% gross margin, driven by high pharma client demand. New ad products grew over 100% y/y, now contributing >20% of pharma revenue, showing strong underlying demand and expanding advertiser engagement.
Positive
FXEmpire
1 week ago
Doximity Momentum, Big Money Support Stays Strong
Shares of Doximity, Inc. (DOCS) jump on business growth, investor inflows.
Neutral
Business Wire
1 week ago
Doximity to Participate in the Raymond James 46th Annual Institutional Investors Conference
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Anna Bryson, CFO, will present at the Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025, at 10:25 a.m. Eastern Time/7:25 a.m. Pacific Time. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians acr.
Positive
Zacks Investment Research
1 week ago
Doximity (DOCS) is an Incredible Growth Stock: 3 Reasons Why
Doximity (DOCS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Positive
Zacks Investment Research
1 week ago
Why Doximity (DOCS) Might be Well Poised for a Surge
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Positive
Zacks Investment Research
1 week ago
Doximity (DOCS) is a Great Momentum Stock: Should You Buy?
Does Doximity (DOCS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Positive
Seeking Alpha
1 week ago
Doximity Q3 Earnings: Outpacing Even Management's Expectations
I previously rated Doximity, Inc. a buy due to strong Q2 earnings, favorable DCF analysis, and its strategic position in the healthcare industry. Q3 earnings showed continued strength, with DOCS stock up 56% compared to the S&P 500's 2% return since my last analysis. Updated DCF valuation, incorporating management guidance and industry trends, suggests a new price target of $90, indicating 14% upside from today.
Positive
Benzinga
2 weeks ago
Digital Health Platform Doximity Stock Jumps On Upbeat Annual Outlook, Analysts Raise Forecast
Doximity Inc DOCS stock is trading higher on Friday after the company reported third-quarter fiscal 2025 results that beat analysts' expectations and upbeat guidance.
Positive
The Motley Fool
2 weeks ago
Why Doximity Stock Skyrocketed Higher Today
According to data provided by S&P Global Market Intelligence, the "Bloomberg platform for medical professionals," Doximity (DOCS 33.69%), saw its shares spike 34% as of 11:20 a.m. ET Friday.
Charts implemented using Lightweight Charts™